Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

被引：12

作者：

Srinivasan, Ramaprasad

Donskov, Frede

Iliopoulos, Othon

Rathmell, Wendy Kimryn

Narayan, Vivek

Maughan, Benjamin L.

Oudard, Stephane

Else, Tobias

Maranchie, Jodi K.

Welsh, Sarah Joanne

Roy, Ananya

Liu, Yanfang

Perini, Rodolfo F.

Linehan, W. Marston

Jonasch, Eric

机构：

[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

[2] Aarhus Univ Hosp, Aarhus, Denmark

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[6] Univ Penn, Philadelphia, PA 19104 USA

[7] Univ Utah, Salt Lake City, UT USA

[8] Hop Europeen Georges Pompidou, Paris, France

[9] Univ Michigan, Ann Arbor, MI 48109 USA

[10] Univ Pittsburgh, Pittsburgh, PA USA

[11] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[12] Merck & Co Inc, Kenilworth, NJ USA

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4555

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4555

引用

页数：3